Update: there is an MDL.
Federal lawsuits filed by or on behalf of men who allegedly suffered a heart attack, stroke, blood clot, or other injury caused by side effects of low testosterone drugs have prompted the need for centralization of the cases. But, with more than 74 product liability lawsuits filed in the federal court system against Testosterone drug makers, not quite everyone is on board for the creation of an MDL (multidistrict litigation).
Last month, a Plaintiff filed a motion seeking to centralize all federal AndroGel lawsuits before one judge for coordinated handling during pretrial proceedings. Most of the cases filed involve Androgel, which accounts for approximately 60% of the testosterone replacement therapy market, though other claims have been filed against AndroDerm, Testim, Axiron, Foresta, and Depo-Testosterione. Subsequent to the filing of the motion to centralize AndroGel cases, a second motion was filed by a group of plaintiffs, seeking to consolidate all federally filed testosterone drug lawsuits. In response, Auxilium Pharmaceuticals, Inc., maker of Testim and Testopel, opposed the request indicating that it is only named in seven of the cases, and therefore an MDL is not warranted.